Algeta US Celebrates Official Opening of Operational Center in Cambridge, MA
Algeta ASA celebrated the official opening of the offices and facilities of Algeta US in Cambridge, Massachusetts.
In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of Alpharadin. Under the terms of the agreement, Bayer will develop, apply for global health authority approvals and commercialize Alpharadin globally, and Algeta will co-promote it with Bayer in the US.
“Algeta Group’s expansion to the US is an important step toward realizing our vision for building a global oncology company commercializing innovation. We have brought on experienced sales, marketing and medical affairs executives to build our US commercial operation and plan to deliver a phased build-up of resources in anticipation of a US commercial launch, with Bayer, of Alpharadin if approved by FDA. We look forward to contributing to the commercial success of the Massachusetts biotech economy and joining the region’s growing group of commercial-stage companies,” said Jeff Albers, President Algeta US.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.